Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis

BackgroundAnthracyclines are key for acute myeloid leukemia (AML) but carry serious side effects. This study identifies their side effects across drugs and patient populations using the FDA Adverse Event Reporting System (FAERS).Materials and methodsWe analyzed 1,079 AML cases and 3,622 adverse events (AEs) from FAERS (2004–2024). Disproportionality analyses (PRR, ROR, BCPNN, MGPS) detected AE signals; Kruskal–Wallis tests evaluated time-to-onset by age/sex.ResultsDistinct risks emerged: epirubi